Harold MD - NanoVibronix Chief Director

NanoVibronix Management Efficiency

The company has return on total asset (ROA) of (0.2957) % which means that it has lost $0.2957 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4059) %, meaning that it created substantial loss on money invested by shareholders. NanoVibronix's management efficiency ratios could be used to measure how well NanoVibronix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.58 in 2024. Return On Capital Employed is likely to climb to -0.77 in 2024. At this time, NanoVibronix's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 205.1 K in 2024, whereas Other Current Assets are likely to drop slightly above 44.6 K in 2024.

Similar Executives

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York. Nanovibronix operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. NanoVibronix (NAOV) is traded on NASDAQ Exchange in USA. It is located in 969 Pruitt Avenue, Tyler, TX, United States, 77569 and employs 10 people. NanoVibronix is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

NanoVibronix Leadership Team

NanoVibronix Stock Performance Indicators

Additional Tools for NanoVibronix Stock Analysis